Firm introduces weaker, longer life vaccine

By Associated Press

Jan 31, 2021 12:14 am

RHODE ISLAND: The first one-shot Covid-19 vaccine provides good protection against the illness, Johnson & Johnson reported in a key study released on Friday, offering the world a potentially important new tool as it races to stay ahead of the rapidly mutating virus.

ONE-SHOT DEAL This September 2020 photo provided by Johnson & Johnson shows a clinician preparing to administer investigational Janssen COVID-19 vaccine. Johnson & Johnson's long-awaited Covid-19 vaccine appears to protect against symptomatic illness with just one shot – not as strong as some two-shot rivals but still potentially helpful for a world in dire need of more doses. Johnson & Johnson said on Jan. 29, 2021 that in the US and seven other countries, the first single-shot vaccine appears 66 percent effective overall at preventing moderate to severe Covid-19. It was more protective against severe symptoms at 85 percent. AP

Already have an active account? Log in here to continue reading.
Or
Subscribe to the Premium Subscription plan to access this subscriber-exclusive article.